The Tasly-backed hepatitis C drug developer priced its shares in the middle of their range and is set to float at the start of next month.
Ascletis, a China-based hepatitis C drug developer backed by pharmaceutical company Tasly Pharmaceuticals, has priced $400m in an initial public offering in Hong Kong, Reuters reported yesterday.
The company floated in the middle of its range, selling 224 million shares equating to 20% of its overall share capital priced at HK$14 ($1.78) each, in the middle of the IPO’s HK$12 to HK$16 range, according to three sources.
Singaporean sovereign wealth fund GIC committed last week to buy $75m of shares…
